afternoon, all Thank and thank us. you you, Matt. joining for Good
progress in operating significant marked as company meaningful programs as a Avinger's shift well forward. structure we our our for quarter therapeutic move as second The
for new in strategic our second the partnership and our opens of announcement with Greater to the pathway balance investment sheet the market, substantial partner improved a Avinger which in image-guided China provided devices further Following a the -- introduction March our we Zylox-Tonbridge, quarter. of
announced providing offering, in equity debt public in conversion million growth The to new stockholders' an convertible closing $XX we which In $XX up million the stock, June, the increased a up announced amount. May, included preferred upfront same the coronary a financing. to available exercise $X the series $XX million based clinical In by with financing by held warrants. of full million milestone-linked upon of additional in shares at CRG we of of of
that cost field operating In us we allows also our by reduced implemented product focus June, we sales of as coronary cost and savings peripheral development support program. cost team's emphasize device count our approximately business users existing of the increase program on reduction streamlines operating an program our This peripheral to our XX%. head
We the seen period. expect XXXX half and the in reduced margin costs the cost reductions to be with both full effect gross of second in operating improved anticipated of the
Turning in operating accomplishments some quarter. to key the the of
we prepare as filing with make FDA. on for the product our to first IDE continued We an progress coronary exciting submission
of the of testing, crossing CTO the the are and device. of initial an verification with Pending for completion completing We quarter. by the process clinical FDA our anticipate the site in third studies Phase remaining selection proprietary validation application IDE filing successful and III we end
coronary provides our market. to condition and to challenging brings new device our for initiate approval closer making and first underserved since Avinger submission arteries. believe system proprietary a complex our device this coronary large redefine the to of clinical step study allow for one IDE available this FDA to and is opportunity image-guided critical Avinger physicians groundbreaking first the step us treating human This the would a in We
we solution occlusions total for high the successful our CTOs. and can simplified failure and crossing today image-guided coronary chronic rate. By a expensive clinically more technology, physicians superior, typically a leveraging we arteries in proprietary documented complex, a procedure is believe coronary with time-consuming provide Crossing with
deployed design success guidance that catheter procedure We and into which our needed real-time precise significantly low-profile a to X and facilitate the improve technologies an with to have expect French OCT we antegrade control approach, steerability times combines crossing reduce rates.
is properly peripheral incorporates optimal outcomes. catheters, device to balloons physicians to our capability placement, coronary help stents size Like a which measurement precise critical prior or our for
practice. completing studies our extensive heart limiting and which control and cadaver can combination and vessel unique during also physicians within animal peripheral and experience our to are our during and profile allow clinical with iodine-containing on confident physicians image development we health pose the expect OCT-guided a robust our less devices onboard patients.
Based arteries, process radiation support cross image-guided reliance therapy CTOs reentry of system safety exposure significant risks support multiple the usage coronary wires, in to guidance catheters We precise x-ray while of specialty and will dye, on contrast with to
dynamics. existing We expect adoption benefit system crossing of our coronary reimbursement to CTO from
will FDA crossing arteries. coronary reimbursement access coronary device high-value the clearance, immediately existing in Following our CTO codes for
are a our imaging access peripheral markets reimbursement currently also key discrete OCT codes crossing differentiator and expect system coronary image-guided existing CTO to reimbursement imaging diagnostic with OCT available. the We device. not This where from diagnostic same for codes for is the
media dynamics, cost for we the updates to require the quarters. coming fewer allow addition further regulatory significant to look of providing progress in crossing and devices, revolutionary for expect the would to forward accessory our of contrast in hospital all through less reimbursement the and on system. excited We're use process reduced savings advance this our attractive result coronary clinical CTO crossing product usage to and which time, In system
proximity business, ensure have our opportunities peripheral on reps while current While to for disease. specialists available growth we've artery sales in field We've patients existing and users operations close are treat accounts. image-guided and our reduced supporting presence seeking to with to focusing a streamlined head existing count and in our or peripheral sales territories catheters clinical steps taken maintained within remain we clinically-challenging
strategy of clinical look endovascular we joined this team. has Center several team image-guided practicing therapies in interventional technologies, of week, the Davis an of investigator and Dr. Medical conferences the podium one cardiologist Officer.
Dr. Cardiovascular Director have John Davis Underscoring importance serves studies. image-guided Avinger's on Chief addition leaders Davis with has the Dr. authored for community. We're development. including for as and to Medical interventional joined our development Dr. the on medical and and excited as the a earlier or Research Detroit, Michigan in to affairs an advance trials extensively clinical leadership as new several multiple publications, Avinger new clinical announced our numerous investigator vascular and in him boards our at to in participated a and presented of to commitment Davis, initiatives Tom medical preeminent programs our the has approach, and of device product on disease at broader important working clinical clinical served clinical to closely drive St. Avinger's forward scientific advisory awareness treatment Hospital of and principal
the the and our are new full commercialization introduction phase along in for of in We've half of atherectomy the our product LV catheter also products, completed XXXX. commercial made coming in new Pantheris peripheral the catheter important We've of with building crossing Tigereye of second ST limited weeks. inventory progress our launch new peripheral launch the
our launch atherectomy Pantheris platform. outcomes mainstream of for larger physicians large the console, image-guided LV we're hands new Pantheris performed more for Pantheris to LV the behind the the Our we in And treatment limited and LV higher balloon does the the arteries name, at our the see to expand PAD is above rotational current and from vessel. knee, Lightbox new variable speeds commercial RPMs. X,XXX the with image-guided our speeds on of learnings where procedures system ideal are operates to get launch imaging LV consistent offerings designed plaque excited for delivering of our majority not Based the of its the combination significantly appeal through physicians require LV atherectomy into streamline with up procedure a with stands atherectomy with device, and than and apposition X today.
Pantheris streamlined process. is clinical
close, quick our on update partnership with like strategic also I'd Zylox-Tonbridge. a I to provide Before
Zylox reminder, markets state-of-the-art neurovascular fully and a integrated China. Greater has vascular in China in extensive facility network manufacturing company peripheral maintains the a in medical a and is and As leader launched device an Hangzhou, market, developed sales and into marketing Zylox the a and China. operates products numerous
Greater are we as catheters closing regulatory products. tranche to approval of professionalism first in peripheral We Zylox's our products the well investment the with for worked their market to their in to excited Avinger's sell of closely Zylox's $X.X more goal support Since China region in in organization gaining the their Zylox efforts teams not establishing million own as China capability operating support March, image-guided our impressed manufacturing XXXX. and in could the be commercializing with
China. be until in sale sell sales finished Avinger. And will are territory bearing Zylox will As approval, in royalty previously disclosed, Zylox regulatory Avinger for of Avinger to to products products following available the their goods self-manufactured
of capability to In for own this from FDA, We products Avinger's provide opportunity Avinger and believe goods their improve source qualified of expense margin registered the have product the the been the overhead addition, finished to manufacturing a sold, in and has with cost reduce reduce option future. and manufacturer Zylox related will successfully U.S. Avinger once Zylox. as gross facility could
and results. At for I'll Nabeel turn to Principal point, Financial Officer Nabeel? the to Officer then this through over call to us Subainati, take the return financial I'd Q&A. like our Accounting
